A defi ning moment in the global AIDS response has been reached. The discourse is no longer about HIV prevention or HIV treatment; it is now about HIV control through the implementation of antiretrovirals as key components of combination interventions. Barely a year ago, visions of HIV control would have been considered far-fetched. The impetus for this change in mindset, which has been building since the XVIII International AIDS Conference in Vienna last year, emanates from the compelling evidence that antiretroviral drugs prevent HIV infection in the general heterosexual population, which is released this week and presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome by the Partners PrEP 1 and Botswana TDF2 2 trials. The Partners PrEP trial, 1 involving 4758 HIV discordant couples from Kenya and Uganda, found that daily oral tenofovir disoproxil fumarate (TDF) and TDFemtricitabine reduced HIV transmission by 62% and 73%, respectively. The Bostwana TDF2 trial, 2 in 1200 heterosexual men and women from the general population, found that daily oral TDF-emtricitabine reduced HIV transmission by 63%. These fi ndings follow close on the heels of the CAPRISA 004 trial 3 of tenofovir gel, the iPrEX trial 4 of oral TDF-emtricitabine in men who have sex with men, and the HPTN 052 trial 5 of early antiretroviral treatment as HIV prevention. Importantly, these new fi ndings fi ll a critical gap in HIV prevention with a readily available antiretroviral approach to prevent heterosexual transmission in both men and women (fi gure). Women benefi t from a new prevention option under their control, which is particularly important for those not assured of their partner's fi delity or willingness to use a condom. The hope these studies add to HIV prevention is further bolstered by the recent step taken by the pharmaceutical company Gilead Sciences Inc to lodge TDF and emtricitabine with the UNITAID patent pool, 12 thus enabling lower cost versions of the drugs to be manufactured and thereby facilitating wider access in poor countries.
There is now no doubt that antiretroviral drugs prevent HIV infection. However, important scientifi c questions remain. Does the inclusion of emtricitabine in pre-exposure prophylaxis (PrEP) formulations provide suffi cient additional benefi t to warrant the additional costs and side-eff ects? Are levels of eff ectiveness and safety similar for daily use and use-with-sex of PrEP? Do the safety, eff ectiveness, cost, and acceptability Efficacy (%) Figure: HIV prevention technologies shown to be eff ective in reducing HIV incidence in randomised controlled trials 1--11 PrEP=Pre-exposure prophylaxis. *Meta-analysis of circumcision trials.
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profi les of oral and topical PrEP merit implementation of both formulations? Does PrEP lead to masking of HIV acquisition that is then revealed once PrEP is withdrawn? Can the new results be generalised to the type of hyperendemic settings (HIV incidence more than 5% per annum) where the FEMPrEP trial 13 was done? Since inadequate drug levels may not have been responsible for the lack of eff ectiveness observed in the FEMPrEP study, 14 the search for an explanation for this intriguing and contrary result needs to be pursued with vigour.
There are also many practical questions about implementation: how to increase uptake of HIV testing; 15 how often to monitor HIV status in people on PrEP; how to achieve high coverage in those at highest risk; how to maintain high levels of adherence; how to reduce the risk of migration away from condoms (behavioural disinhibition); and how to monitor the risk of drug resistance. While attempts are being made to obtain data to address these questions and to generate data to guide eff ective implementation, the development of normative guidance by WHO/UNAIDS and submissions for regulatory approvals of TDF and TDF-emtricitabine as PrEP for HIV infection are key next steps.
As antiretroviral drugs take a key role in the global eff ort to control the HIV epidemic, there is much to be learned from the contraceptive fi eld where multiple technologies, approaches, formulations, and dosing options were developed to enable and maximise user choice and increase levels of uptake, coverage, and adherence and thereby improve the public health impact.
Beyond the questions of implementation, the future scientifi c challenge looming large for PrEP is fi nding a drug or class of drugs with a resistance profi le that does not interfere with existing fi rst-line and second-line AIDS treatment. Treatment of HIV-positive people for HIV prevention and PrEP and microbicides for HIV-negative people are two sides of the same coin, and cannot be viewed in isolation from each other. Although research on treatment for prevention, PrEP, and microbicides has mostly occurred in separate silos, their fi ndings converge into a single focus in HIV prevention and necessitate guidance on how to use all three strategies synergistically for maximum benefi t depending on the nature of the HIV epidemic. There is no magic bullet for the HIV epidemic. Treatment for prevention will be dependent on the extent to which couples establish their HIV status, whether the HIV-positive partner in a discordant couple adheres to therapy, and whether the HIV-negative partner maintains fi delity within the partnership. PrEP will be dependent on the extent to which people seek to establish and regularly monitor their HIV status and those on PrEP adhere to their regimen and clinical monitoring. Hyper-endemic communities, such as those in South Africa where HIV prevalence in the community is high, may require both interventions jointly and synergistically: treatment of people infected with HIV to reduce risk of transmission within the discordant couple, and PrEP to reduce the HIV-negative partner's risk of HIV acquisition from outside partners.
Therein lie the three most complex policy, implementation, fi scal, and ethical challenges generated by these new fi ndings. First, how to scale up HIV testing, a key prerequisite in settings with stigma and discrimination. Second, how to extend antiretrovirals for both treatment and prevention when many of Africa's health systems are already struggling to cope with patients with AIDS and are not able to initiate antiretroviral therapy in everyone who currently needs it for their survival. Third, in the context of limited resources how best to ration and prioritise the limited available implementation capacity.
In this defi ning moment in the response to HIV, a global commitment to increased fi nancial resources for implementation, health systems strengthening, and greater implementation effi ciency is imperative. Anything less will crush the hope and promise that antiretroviral drugs can change the course of the HIV epidemic.
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